BPNT2

Across TCGA pan-cancer cohorts, BPNT2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated BPNT2 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher BPNT2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated BPNT2 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

CCRCC, LUAD, and HNSC are the cancer types where BPNT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	All	0.633	1.000	.005	21	view →
LUAD	OS	Tertile	III,IV	0.876	0.227	.011	13	view →
HNSC	DFS	Quartile	All	0.317	0.715	.047	4	view →
LSCC	DFS	Quartile	All	0.847	0.999	.029	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

BPNT2–CCRCC (OS)

Open the CCRCC breakdown →